- €99.10m
- €191.49m
- €155.98m
- 49
- 89
- 23
- 53
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 113 | 129 | 178 | 156 | 156 |
Cost of Revenue | |||||
Gross Profit | 62.4 | 79 | 93.5 | 77.8 | 92.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 99.6 | 109 | 150 | 143 | 139 |
Operating Profit | 13.5 | 20.6 | 27.5 | 13.3 | 17.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 13 | 20 | 26 | 13.4 | 15 |
Provision for Income Taxes | |||||
Net Income After Taxes | 10.7 | 15.3 | 18.2 | 9.97 | 12.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 10.7 | 15.2 | 18.2 | 9.98 | 12.8 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10.7 | 15.3 | 17.8 | 12.9 | 9.45 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.136 | 0.225 | 0.206 | 0.156 | 0.068 |
Dividends per Share |